The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
Open accessAbstract
// Ruea-Yea Huang 1, 2 , Cheryl Eppolito 1, 2 , Shashikant Lele 1 , Protul Shrikant 4 , Junko Matsuzaki 1, 2, 3 , Kunle Odunsi 1, 2, 3 1 Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA 2 Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA 3 Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York, USA 4 Department of Research, Mayo Clinic, Scottsdale, Arizona, USA Correspondence to: Kunle Odunsi, e-mail: kunle.odunsi@roswellpark.org Ruea-Yea Huang, e-mail: raya.huang@roswellpark.org Keywords: LAG3, PD1, antibody blockade, T cell signaling, ovarian cancer Received: March 05, 2015 Accepted: July 10, 2015 Published: July 23, 2015 ABSTRACT The immune co-inhibitory receptors lymphocyte activation gene-3 (LAG3) and programmed cell death 1 (PD1) synergistically contribute to autoimmunity and tumor evasion. Here we demonstrate how they collaborate and interact to regulate T cell function. We first show that LAG3 and PD1 are co-expressed on both OVA-specific and non-specific T cells infiltrating murine ovarian tumors. Dual antibody blockade or genetic knockout of LAG3 and PD1 significantly enhanced T effector function and delayed tumor growth. LAG3 and PD1 co-localized in activated CD8 + T cells in vitro at the trans-Golgi vesicles, early/recycling endosomal compartments, lysosomes, and microtubule organizing center. Importantly, LAG3 and PD1 cluster with pLck at the immunological synapse. Reciprocal immunoprecipitation of T cell extracts revealed physical interaction between LAG3 and PD1. Mutational analyses indicate that the cytoplasmic domain of LAG3 is not absolutely required for its association with PD1, while the ITIM and ITSM of PD1 are necessary for its association with LAG3. Finally, LAG3 protein also associates with the Src-homology-2 domain-containing phosphatases (SHP1/2) which are known to be recruited by PD1 during T cell signaling. Our data indicate that the association of LAG3 with PD1 contributes to their rapid trafficking to the immunological synapse, leading to a synergistic inhibitory effect on T cell signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593
Liang, B., Workman, C., Lee, J., Chew, C., Dale, B. M., Colonna, L., Flores, M., Li, N., Schweighoffer, E., Greenberg, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5916 · Cited by 566
Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3
Workman, C. J., Dugger, K. J., & Vignali, D. A. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5392 · Cited by 389
Workman, C. J., Cauley, L. S., Kim, I.-J., Blackman, M. A., Woodland, D. L., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5450 · Cited by 351
Research works printed but not linked: 37
- Allison, 2010, Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy, Semin Oncol, 37, 473, 10.1053/j.seminoncol.2010.09.001 · DOI · Paper page
- Michielin, 2012, Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization, PLoS One, 7, e30852, 10.1371/journal.pone.0030852 · DOI · Paper page
- Ahmed, 2006, Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, 439, 682, 10.1038/nature04444 · DOI · Paper page
- Totterman, 2010, Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy, J Immunother, 33, 225, 10.1097/CJI.0b013e3181c01fcb · DOI · Paper page
- Honjo, 1996, Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes, Int Immunol, 8, 765, 10.1093/intimm/8.5.765 · DOI · Paper page
- Allison, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci U S A, 107, 4275, 10.1073/pnas.0915174107 · DOI · Paper page
- Odunsi, 2010, Tumor-infiltrating NY-ESO-1-specific CD8T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proc Natl Acad Sci U S A, 107, 7875, 10.1073/pnas.1003345107 · DOI · Paper page
- Mathis, 1996, Independent modes of natural killing distinguished in mice lacking Lag3, Science, 272, 405, 10.1126/science.272.5260.405 · DOI · Paper page
- Honjo, 2011, PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice, J Exp Med, 208, 395, 10.1084/jem.20100466 · DOI · Paper page
- Sidorenko, 2001, CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A, J Immunol, 166, 5480, 10.4049/jimmunol.166.9.5480 · DOI · Paper page
- Clark, 2003, The dual-function CD150 receptor subfamily: the viral attraction, Nat Immunol, 4, 19, 10.1038/ni0103-19 · DOI · Paper page
- Piatier-Tonneau, 1992, Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens, J Exp Med, 176, 327, 10.1084/jem.176.2.327 · DOI · Paper page
- Triebel, 1998, CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling, J Immunol, 161, 4058, 10.4049/jimmunol.161.8.4058 · DOI · Paper page
- Vignali, 2003, The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells, Eur J Immunol, 33, 970, 10.1002/eji.200323382 · DOI · Paper page
- Donini, 1996, Cloning of murine LAG-3 by magnetic bead bound homologous probes and PCR (gene-capture PCR), Anal Biochem, 241, 93, 10.1006/abio.1996.0382 · DOI
- Vignali, 2004, Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3, CD223), J Immunol, 173, 6806, 10.4049/jimmunol.173.11.6806 · DOI
- Chun, 2014, Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling, J Immunol, 193, 3101, 10.4049/jimmunol.1401025 · DOI
- Vignali, 2010, Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4, Eur J Immunol, 40, 1768, 10.1002/eji.200939874 · DOI
- Allison, 2007, Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability, Proc Natl Acad Sci U S A, 104, 17765, 10.1073/pnas.0708767104 · DOI
- Allison, 2004, B7-1 and B7–2 selectively recruit CTLA-4 and CD28 to the immunological synapse, Immunity, 21, 401, 10.1016/j.immuni.2004.06.017 · DOI · Paper page
- Triebel, 2005, The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells, Immunology, 115, 170, 10.1111/j.1365-2567.2005.02145.x · DOI · Paper page
- Kupfer, 1998, Three-dimensional segregation of supramolecular activation clusters in T cells, Nature, 395, 82, 10.1038/25764 · DOI · Paper page
- Poenie, 2002, Dynamic polarization of the microtubule cytoskeleton during CTL-mediated killing, Immunity, 16, 111, 10.1016/S1074-7613(02)00262-5 · DOI · Paper page
- Griffiths, 2006, Centrosome polarization delivers secretory granules to the immunological synapse, Nature, 443, 462, 10.1038/nature05071 · DOI · Paper page
- Ahmed, 2011, Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells, Immunity, 35, 400, 10.1016/j.immuni.2011.06.015 · DOI · Paper page
- Honjo, 2001, PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine, Proc Natl Acad Sci U S A, 98, 13866, 10.1073/pnas.231486598 · DOI · Paper page
- Chaudhary, 2004, PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta, FEBS Lett, 574, 37, 10.1016/j.febslet.2004.07.083 · DOI · Paper page
- Triebel, 1999, The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes, Int Immunol, 11, 1745, 10.1093/intimm/11.11.1745 · DOI
- Guo, 2013, Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin, PLoS One, 8, e84927, 10.1371/journal.pone.0084927 · DOI
- Ullrich, 1996, Multiplephosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584, Cell Growth Differ, 7, 1589
- Chardin, 1994, Binding of the Grb2 SH2 domain to phosphotyrosine motifs does not change the affinity of its SH3 domains for Sos proline-rich motifs, Embo J, 13, 4011, 10.1002/j.1460-2075.1994.tb06717.x · DOI
- Triebel, 2003, MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223), Blood, 102, 2130, 10.1182/blood-2003-01-0273 · DOI
- Yamamoto, 2009, CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2, Proc Natl Acad Sci U S A, 106, 13974, 10.1073/pnas.0906872106 · DOI · Paper page
- Carbone, 1994, T cell receptor antagonist peptides induce positive selection, Cell, 76, 17, 10.1016/0092-8674(94)90169-4 · DOI · Paper page
- Mathis, 1996, LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice, Int Immunol, 8, 725, 10.1093/intimm/8.5.725 · DOI
- Honjo, 1996, Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes, Int Immunol, 8, 773, 10.1093/intimm/8.5.773 · DOI · Paper page
- Bevan, 1988, Introduction of soluble protein into the class I pathway of antigen processing and presentation, Cell, 54, 777, 10.1016/S0092-8674(88)91043-4 · DOI · Paper page
Cited by
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
LAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Andrews, L. P., Yano, H., & Vignali, D. A. A. (2019) · Nature Immunology · doi:10.1038/s41590-019-0512-0 · Cited by 543
LAG-3: from molecular functions to clinical applications
Maruhashi, T., Sugiura, D., Okazaki, I.-M., & Okazaki, T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001014 · Cited by 459
A versatile system for rapid multiplex genome-edited CAR T cell generation
Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15218 · Cited by 397
Metadata
- Authors
- Huang, R.-Y., Eppolito, C., Lele, S., Shrikant, P., Matsuzaki, J., & Odunsi, K.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-07-23
- Volume
- 6
- Issue
- 29
- Pages
- 27359-27377
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2132020367
- Cited by
- 308
- References
- 14
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.